Composition
- Tablets :Each tablet contains: Terbinafine hydrochloride 277 mg (Equivalent to 250 mg terbinafine base).
- Cream 1% – Each one gram contains Terbinafine hydrochloride 10 mg.
Properties
Terbinafine HCl (Fungisafe®) is a synthetic allylamine derivative that exerts its antifungal effect by inhibiting squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This action results in a deficiency in ergosterol and a corresponding accumulation of squalene within the fungal cell causing fungal cell death.
It is fungicidal against dermatophytes (Trichophyton spp., Microsporum spp. & Epidermophyton spp.), mold fungi & some yeasts.
Pharmacokinetic properties
Fungisafe Tablets
Terbinafine HCl (Fungisafe®) is well absorbed from the gastro-intestinal tract.
Bioavailability is 80% and is not affected by the presence of food. Mean peak plasma concentrations of about 1ug/ml are reported within 2 hours of a single oral dose of 250 mg.
Terbinafine is extensively bound to plasma proteins (99%).
Fungisafe® is distributed into the stratum corneum of the skin, the nail plate & hair where it reaches concentrations considerably higher than those found in plasma.
Terbinafine (Fungisafe®) is metabolised in the liver to inactive metabolites.
Approximately 80% of an administered dose is excreted in the urine as metabolites and the remainder in feces.
A plasma elimination half-life varying from 11-17 hours has been reported and a terminal elimination half-life of up to 400 hours in patients receiving prolonged therapy, probably representing elimination from skin & adipose tissue.
The elimination rate may be altered in patients with liver or kidney diseases.
Fungisafe Cream
Less than 5% of the topically applied terbinafine cream is absorbed.
The elimination half-life of topically absorbed terbinafine is 21 hours.
Approximately 75% of topically absorbed.
Indications
Fungisafe Tablets
- Dermatophyte infections of skin & hair (tinea pedis, tinea corporis, tinea cruris and tinea capitis).
- Dermatophyte infections of finger and toenails (onychomycosis).
Fungisafe Cream
Dermatophyte infections of the skin including:
- Tinea pedis, tinea corporis, tinea cruris.
- Pityriasis versicolor.
- Cutaneous candidiasis.
Dosage
Fungisafe Tablets
- For onychomycosis: The usual oral dose is one tablet (250 mg) once daily for 6 weeks (fingernails) and for 12 weeks (toenails).
- For dermatophytes of the skin: The usual oral dose is one tablet (250 mg) once daily for 2-4 weeks in tinea corporis and tinea cruris &for 2-6 weeks in tinea pedis.
- For tinea capitis: the dose is one tablet (250 mg) once daily for 4 weeks.
Patients with renal impairment (creatinine clearance < 50 ml/min) or patients with pre-existing stable chronic liver disease, should receive half the usual dose of terbinafine.
Fungisafe tablets for Children:
- No data are available in children under two years of age (usually < 12 kg).
- < 20 kg body weight: 62.5 mg daily.
- 20-40 kg: 125 mg daily.
- 40 kg: 250 mg daily.
Fungisafe Cream
Tinea pedis: Between the toes only: apply twice daily for 1 week. On the bottom or sides of the foot: apply twice daily for 2 weeks.
Tinea corporis , tinea cruris: apply once or twice daily for 1-2 weeks.
Pityriasis versicolor & cutaneous candidiasis: apply once or twice daily for 2 weeks.
Patients information
- Use the tip of the cap to break the seal & open the tube.
- Wash the affected skin with soap & water and dry completely before application of cream.
- Apply the cream to the affected skin and surrounding area in a thin layer and rub in lightly.
- Wash hands after each use.
How Supplied
- Tablets: Strips of 7 tablets in packs of one strip.
- Cream: Tubes of 15 gm.
Keep all medicaments out of reach of children
Product of: AMOUN PHARMACEUTICAL CO. El-Obour City, Cairo, Egypt. ATC Code: D01BA02
Dr. Ahmad Baker, PharmD
Senior Pharmacist & Health Educator
With over 23 years of clinical experience in hospital and community pharmacy across Egypt and Saudi Arabia, Dr. Ahmad specializes in reproductive health and pharmaceutical safety. He is dedicated to providing evidence-based guidance to empower patients in the MENA region.
Medical Disclaimer: This content is for educational purposes and reflects the latest pharmaceutical protocols. It is not a substitute for personal medical advice. Always consult Dr. Ahmad Baker or your healthcare provider before starting any treatment.

